<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795756</url>
  </required_header>
  <id_info>
    <org_study_id>NILG-ALL 10/07</org_study_id>
    <nct_id>NCT00795756</nct_id>
  </id_info>
  <brief_title>Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Randomized Study on CNS Prophylaxis With Liposome-Encapsulated Cytarabine in Association With a Lineage-Targeted and MRD-Oriented Postremission Strategy in Adult ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Italy Leukemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northern Italy Leukemia Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical study in adult ALL is to compare by risk category (1) the&#xD;
      feasibility of two different CNS prophylaxis regimens and (2) the overall disease-free&#xD;
      survival in relation to the achievement of an early MRD negative status and following&#xD;
      consolidation with lineage-targeted methotrexate infusions and other disease-specific&#xD;
      therapeutic elements, with or without the application of allogeneic or autologous SCT&#xD;
      depending on risk class and MRD study results.&#xD;
&#xD;
      In this multicentric prospective pilot randomized phase II trial on CNS prophylaxis, all&#xD;
      patients receive induction/consolidation therapy incorporating lineage-targeted high-dose&#xD;
      methotrexate plus other drugs (with additional imatinib in Ph/BCR-ABL+ ALL), for the&#xD;
      achievement of an early negative MRD status. The MRD study supports a risk/MRD-oriented final&#xD;
      consolidation phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A) Risk Classification&#xD;
&#xD;
      Newly diagnosed patients are hierarchically clustered into very high, high and standard risk&#xD;
      cases (VHR, HR, SR) using international risk criteria modified according to NILG:&#xD;
&#xD;
      A1) VHR (any criterium): B-precursor: WBC count &gt;100x109/L; adverse cytogenetics/molecular&#xD;
      biology such as t(9;22)/BCR-ABL, t(4;11)/MLL rearrangement at 11q23, +8, -7, del6q, t(8;14),&#xD;
      low hypodiploidy with 30-39 chromosomes, near triploidy with 60-78 chromosomes, complex with&#xD;
      &gt;5 unrelated anomalies. T-precursor: WBC count &gt;100x109/L; early/late non-cortical&#xD;
      immunophenotype (CD1a-); adverse cytogenetics/molecular biology (as above).&#xD;
&#xD;
      A2) HR (any criterium, VHR excluded): B-precursor: WBC count &gt;30x109/L; pro-B&#xD;
      immunophenotype; complete remission after cycle 2. T-precursor: complete remission after&#xD;
      cycle 2.&#xD;
&#xD;
      A3) SR (all criteria, VHR/HR excluded): B-precursor: WBC count &lt;30x109/L; T-precursor: WBC&#xD;
      count &lt;100x109/L; cortical immunophenotype (CD1a+).&#xD;
&#xD;
      B) CNS Prophylaxis Stratification before randomisation&#xD;
&#xD;
        1. by immunophenotype, i.e. B-precursor vs. T-precursor&#xD;
&#xD;
        2. by risk class, i.e. SR vs. non-SR (using only known factors) Randomisation: intrathecal&#xD;
           (IT) CNS prophylaxis with standard triple therapy (TIT, 12 total injections) vs.&#xD;
           DepoCyte (6-8 total injections by disease subset). Cranial irradiation is omitted in&#xD;
           both arms, and all patients receive the same chemotherapy program including CNS-crossing&#xD;
           agents.&#xD;
&#xD;
      C)Induction/Early Consolidation and MRD Study&#xD;
&#xD;
      Randomised patients receive homogeneous induction/early consolidation chemotherapy, including&#xD;
      subset-specific elements for B-precursor ALL (3x targeted-infusion methotrexate 2.5 g/m2),&#xD;
      T-precursor ALL (3x targeted-infusion methotrexate 5 g/m2), age &gt;55 years (methotrexate&#xD;
      reduced to 1.5 g/m2), Ph/BCR-ABL+ ALL (imatinib, reduced-intensity chemotherapy), radiation&#xD;
      therapy (LL). Patients not in CR after cycles 1-2 are off study. For CR evaluation bone&#xD;
      marrow is checked on days 28 and/or 56. Consolidation cycles are administered at 21-28 day&#xD;
      intervals Concurrent MRD analysis is performed at four timepoints (weeks 4, 10, 16 and 22 of&#xD;
      induction/consolidation), to optimize risk classification and support risk/MRD-oriented&#xD;
      therapy:&#xD;
&#xD;
      C1) MRD negative (M-NEG): negative MRD study (&lt;10-4 at timepoints #2 and #3, and negative at&#xD;
      timepoint #4) C2) MRD positive (M-POS): positive MRD study (&gt;10-4 at timepoints #2 or #3, or&#xD;
      positive at timepoint #4)&#xD;
&#xD;
      D)MRD/Risk-Oriented Final Therapy D1) VHR patients are candidate to an early allogeneic SCT&#xD;
      (related/unrelated donor/cord blood; ablative/non-ablative conditioning according to current&#xD;
      protocols/guidelines) after CR, regardless MRD study results.&#xD;
&#xD;
      D2) M-POS as well as HR patients with unknown MRD are allocated to allogeneic SCT after MRD&#xD;
      timepoint 2 (M-POS &gt;10-4) or MRD timepoint 4 (others). When an allogeneic SCT is not&#xD;
      possible, patients complete consolidation and receive autologous-type SCT followed by&#xD;
      maintenance.&#xD;
&#xD;
      D3) M-NEG as well as SR patients with unknown MRD are allocated to maintenance therapy.&#xD;
&#xD;
      Age-limited therapeutic procedures: Patients aged &gt;55 years are treated with age-adapted&#xD;
      therapy, and when indicated will be included in SCT programs whenever possible and according&#xD;
      to performance status and comorbidity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative analysis of feasibility/toxicity of IT DepoCyte vs. TIT</measure>
    <time_frame>weeks 5, 11, 17 and 23</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative analysis of isolated and combined CNS recurrence following TIT vs DepoCyte prophylaxis</measure>
    <time_frame>During study follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR)</measure>
    <time_frame>After study chemotherapy cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow MRD negativity rates</measure>
    <time_frame>Four time-points at weeks 4-22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lenght of remission</measure>
    <time_frame>Study follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Study follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Intrathecal DepoCyte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>I.t. DepoCyte 50 mg admninistered x6-8 (depending on immunophenotypic disease subset) during induction/consolidation/eraly maintenance phases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple intrathecal therapy (TIT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg injected intrathecally x12 during indiction/consolidation phases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposome-encapsulated cytarabine (DepoCyte)</intervention_name>
    <description>DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases</description>
    <arm_group_label>Intrathecal DepoCyte</arm_group_label>
    <other_name>DepoCyte</other_name>
    <other_name>DepoCyt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple intrathecal therapy (TIT)</intervention_name>
    <description>Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy</description>
    <arm_group_label>Triple intrathecal therapy (TIT)</arm_group_label>
    <other_name>Methotrexate</other_name>
    <other_name>Cytosine arabinoside</other_name>
    <other_name>Cytosar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years.&#xD;
&#xD;
          -  Diagnosis of untreated ALL with B-/T-precursor phenotype or B-cell lymphoblastic&#xD;
             lymphoma (B-LL), either de novo or secondary to chemo-radiotherapy for other cancer.&#xD;
&#xD;
          -  Full cytological, cytochemical, cytogenetic and immunobiological disease&#xD;
             characterization by revised FAB, EGIL and WHO criteria.&#xD;
&#xD;
          -  Bone marrow and peripheral blood sampling (ALL) or biopsy specimen (LL) for MRD study.&#xD;
&#xD;
          -  ECOG performance status 0-2 or reversible ECOG 3 score following intensive care of&#xD;
             complications.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of B-ALL (FAB L3 ALL/Burkitt's leukemia or lymphoma) and T-LL (T-cell&#xD;
             lymphoblastic lymphoma).&#xD;
&#xD;
          -  Down's syndrome.&#xD;
&#xD;
          -  Pre-existing, uncontrolled pathology such as cardiac disease (congestive/ischemic,&#xD;
             acute myocardial infarction within the past 3 months, untreatable arrythmias, NYHA&#xD;
             classes III and IV), severe liver disease with serum bilirubin &gt;3 mg/dL and/or ALT &gt;3&#xD;
             x upper normal limit (unless attributable to ALL/LL), kidney function impairment with&#xD;
             serum creatinine &gt;2 mg/dL (unless attributable to ALL/LL), and severe neurological or&#xD;
             psychiatric disorder that impairs the patient's ability to understand and sign the&#xD;
             informed consent, or to cope with the intended treatment plan.&#xD;
&#xD;
          -  Known HIV positive serology.&#xD;
&#xD;
          -  Other active hematological or non-hematological cancer with life expectancy &lt;1 year.&#xD;
&#xD;
          -  Pregnancy (fertile women will be advised not to become pregnant while on treatment;&#xD;
             and male patients to adopt contraceptive methods), unless therapeutic aborption/early&#xD;
             discharge is carried out.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato Bassan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>USC Ematologia, Ospedali Riuniti, Bergamo (Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Ematologia, Ospedale Civile</name>
      <address>
        <city>Alessandria</city>
        <state>(al)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Ematologia, Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <state>(bg)</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>(bs)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia e TMO, Ospedale San Maurizio</name>
      <address>
        <city>Bolzano</city>
        <state>(bz)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e centro TMO - Ospedale Armando Businco</name>
      <address>
        <city>Cagliari</city>
        <state>(ca)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>(cn)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e centro TMO, Istituti Ospedalieri</name>
      <address>
        <city>Cremona</city>
        <state>(cr)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>(fi)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e centro TMO - IRCSS Mangiagalli Regina Elena</name>
      <address>
        <city>Milano</city>
        <state>(mi)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e centro TMO, Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>(mi)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e centro TMO, Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>(mi)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncoematologia e TMO - Dipartimento Oncologico La Maddalena</name>
      <address>
        <city>Palermo</city>
        <state>(pa)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia 2 - Ospedale San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <state>(to)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicina Interna I - Ospedale di Circolo</name>
      <address>
        <city>Varese</city>
        <state>(va)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onco-Ematologia - Ospedale Civile</name>
      <address>
        <city>Noale</city>
        <state>(ve)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <state>(vi)</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>October 21, 2014</last_update_submitted>
  <last_update_submitted_qc>October 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northern Italy Leukemia Group</investigator_affiliation>
    <investigator_full_name>DR RENATO BASSAN</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Adults</keyword>
  <keyword>Central nervous system prophylaxis</keyword>
  <keyword>Minimal residual disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

